Lonza Ltd (quality control testing (except potency, sterility, and bacterial endotoxins))

The drug is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL). It is used for both previously untreated cases (in combination with certain therapy regimens) and for the treatment of relapsed or refractory forms of the disease.

Dosage form: powder for concentrate for infusion solution

ATC: L01FX14

The drug is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL). It is used for both previously untreated cases (in combination with R-CHP) and for the treatment of relapsed or refractory disease (in combination with bendamustine and rituximab).

Dosage form: powder for concentrate for infusion solution

ATC: L01FX14